Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Immune Deficiency: early-phase trial registry

4 of 7 indexed Immune Deficiency trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Immune Deficiency: 7 US clinical trials tracked, 4 recruiting.

Immune Deficiency is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Columbia University, running 2 of these trials.

Enrollment posture brief

Registry condition immune-deficiency

OPEN 4 | RECR 57% | LATE 0 | EARLY 3 | RANK #2497 | SPON 2

Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Immune Deficiency (this)57%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Immune Deficiency

Immune Deficiency lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Immune Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Immune Deficiency is recruiting above its size-band peers.

    4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Immune Deficiency research.

    Columbia University accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Immune Deficiency trials plan to enrol fewer than 100 people.

    Median target enrolment is 18 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.

  4. Immune Deficiency splits between interventional and observational designs.

    4 interventional and 3 observational studies make up this index (57.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13

Phase Distribution

PhaseTrial count
Phase 1 3

Named interventions

Most-linked intervention names on Immune Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

anti-mycoplasma hominis antibodies Biological
1 trials
Institutional standard intravenous immune globulin treatment Drug
1 trials
Haploidentical Natural Killer (NK) Cells Biological
1 trials
genetic restrospective study Genetic
1 trials
Rapidly generated virus specific T (R-MVST) cells Drug
1 trials
Let's Get REAL Behavioral
1 trials

US sites by state

Facility locations filed on Immune Deficiency trials. A trial with sites in several states counts in each.

New York 2 trials
Rhode Island 1 trials
Pennsylvania 1 trials
New Jersey 1 trials
Missouri 1 trials
Minnesota 1 trials
Maryland 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Immune Deficiency page

7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Immune Deficiency condition card totals 7 registered trials; most-linked intervention anti-mycoplasma hominis antibodies; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.